Brief: Madrigal Pharmaceuticals Q2 EPS USD -1.9

Madrigal Pharmaceuticals

05/08/2025 12:00

Overview

Madrigal Q2 2025 net sales rise to $212.8 mln from $14.6 mln year-ago, driven by demand for NASH treatment Rezdiffra

Co secures new U.S. patent for Rezdiffra, extending protection to 2045

Madrigal enters global licensing agreement for oral GLP-1 candidate

Result Drivers

REZDIFFRA DEMAND - Strong demand for Rezdiffra drove Q2 2025 net sales to $212.8 mln, up from $14.6 mln in the prior year period, per CEO Bill Sibold

PATENT EXTENSION - New U.S. patent extends Rezdiffra's protection to 2045, securing long-term market position, according to CEO Bill Sibold

PIPELINE ADVANCEMENT - Madrigal announced a global licensing agreement for an oral GLP-1 development candidate, SYH2086, expected to enter clinical trials in H1 2026

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$212.80 mln
Q2 EPS
-$1.9
Q2 Net Income
-$42.28 mln
Q2 Operating Expenses
$260 mln
Q2 Operating Income
-$47.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Madrigal Pharmaceuticals Inc is $417.50, about 25.2% above its August 4 closing price of $312.11

Press Release: ID:nGNX4qR7vp

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)